This review discusses the multidisciplinary treatment strategy for patients with EGFR-mutated NSCLC, focusing on the appropriate timing of LAT in combination with EGFR-TKIs for those with synchronous oligometastatic disease, oligo-residual disease, and Oligo-PD. Here, EGFR is linked to non-small cell lung carcinoma.